{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:57:31Z","timestamp":1791280651162,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Erasmus MC Mrace efficacy"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.jchromb.2017.06.029","type":"journal-article","created":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T18:30:16Z","timestamp":1497983416000},"page":"367-373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["High-throughput quantification of 8 antihypertensive drugs and active metabolites in human plasma using UPLC\u2013MS\/MS"],"prefix":"10.1016","volume":"1060","author":[{"given":"Bart C.H.","family":"van der Nagel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorie","family":"Versmissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soma","family":"Bahmany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teun","family":"van Gelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit C.P.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jchromb.2017.06.029_bib0005","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJMra1201534","article-title":"Measuring the global burden of disease","volume":"369","author":"Murray","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jchromb.2017.06.029_bib0010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1001\/archinternmed.2007.72","article-title":"Importance of therapy intensification and medication nonadherence for blood pressure control in patients with coronary disease","volume":"168","author":"Ho","year":"2008","journal-title":"Arch. Intern. Med."},{"issue":"5","key":"10.1016\/j.jchromb.2017.06.029_bib0015","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/MLR.0b013e3181d567bd","article-title":"Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs","volume":"48","author":"Dragomir","year":"2010","journal-title":"Med. Care"},{"issue":"38","key":"10.1016\/j.jchromb.2017.06.029_bib0020","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","article-title":"Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences","volume":"34","author":"Chowdhury","year":"2013","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.jchromb.2017.06.029_bib0025","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11906-016-0697-7","article-title":"How to screen for non-adherence to antihypertensive therapy","volume":"18","author":"Gupta","year":"2016","journal-title":"Curr. Hypertens. Rep."},{"issue":"7","key":"10.1016\/j.jchromb.2017.06.029_bib0030","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"31","author":"Mancia","year":"2013","journal-title":"J. Hypertens."},{"issue":"6","key":"10.1016\/j.jchromb.2017.06.029_bib0035","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jash.2015.04.004","article-title":"Comparison of Morisky Medication Adherence Scale with therapeutic drug monitoring in apparent treatment-resistant hypertension","volume":"9","author":"Pandey","year":"2015","journal-title":"J. Am. Soc. Hypertens."},{"issue":"2","key":"10.1016\/j.jchromb.2017.06.029_bib0040","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/jhh.2015.38","article-title":"Non-adherence to antihypertensive medication is very common among resistant hypertensives: results of a directly observed therapy clinic","volume":"30","author":"Hameed","year":"2016","journal-title":"J. Hum. Hypertens."},{"issue":"7","key":"10.1016\/j.jchromb.2017.06.029_bib0045","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/ajh.2012.30","article-title":"Predictors of antihypertensive medication adherence in two urban health-care systems","volume":"25","author":"Grigoryan","year":"2012","journal-title":"Am. J. Hypertens."},{"issue":"1","key":"10.1016\/j.jchromb.2017.06.029_bib0050","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/hr.2010.183","article-title":"Difficult-to-control arterial hypertension or uncooperative patients the assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy","volume":"34","author":"Ceral","year":"2011","journal-title":"Hypertens. Res."},{"issue":"1\u20132","key":"10.1016\/j.jchromb.2017.06.029_bib0055","doi-asserted-by":"crossref","first-page":"65","DOI":"10.20452\/pamw.2648","article-title":"Assessment of adherence to treatment in patients with resistant hypertension using toxicological serum analysis","volume":"125","author":"Florczak","year":"2015","journal-title":"Pol. Arch. Med. Wewn."},{"issue":"1\u20132","key":"10.1016\/j.jchromb.2017.06.029_bib0060","doi-asserted-by":"crossref","first-page":"65","DOI":"10.20452\/pamw.2648","article-title":"Assessment of adherence to treatment in patients with resistant hypertension using toxicological serum analysis. A subgroup evaluation of the RESIST-POL study","volume":"125","author":"Florczak","year":"2015","journal-title":"Pol. Arch. Med. Wewn."},{"issue":"8","key":"10.1016\/j.jchromb.2017.06.029_bib0065","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jacc.2013.10.067","article-title":"Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension","volume":"63","author":"Brinker","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.jchromb.2017.06.029_bib0070","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.4244\/EIJV9I9A185","article-title":"Medication non-adherence as a critical factor in the management of presumed resistant hypertension: a narrative review","volume":"9","author":"De Geest","year":"2014","journal-title":"EuroIntervention"},{"issue":"4","key":"10.1016\/j.jchromb.2017.06.029_bib0075","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/HJH.0b013e32835e2286","article-title":"Resistant hypertension? Assessment of adherence by toxicological urine analysis","volume":"31","author":"Jung","year":"2013","journal-title":"J. Hypertens."},{"issue":"4","key":"10.1016\/j.jchromb.2017.06.029_bib0080","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1751-7176.2009.00102.x","article-title":"Intensive monitoring of adherence to treatment helps to identify true resistant hypertension","volume":"11","author":"de Souza","year":"2009","journal-title":"J. Clin. Hypertens."},{"issue":"4","key":"10.1016\/j.jchromb.2017.06.029_bib0085","first-page":"191","article-title":"Determination of Amlodipine in Human Plasma by LC-MS\/MS and Its Bioequivalence Study in Healthy Chinese Subjects","volume":"4","author":"Chan-Mei","year":"2013","journal-title":"Pharmacol. Pharm"},{"issue":"1\u20132","key":"10.1016\/j.jchromb.2017.06.029_bib0090","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jchromb.2007.02.014","article-title":"A liquid chromatography\/tandem mass spectrometry method for the simultaneous quantification of valsartan and hydrochlorothiazide in human plasma","volume":"852","author":"Li","year":"2007","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"issue":"4","key":"10.1016\/j.jchromb.2017.06.029_bib0095","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/jms.1006","article-title":"Simultaneous determination of spironolactone and its active metabolite canrenone in human plasma by HPLC-APCI-MS","volume":"41","author":"Dong","year":"2006","journal-title":"J. Mass Spectrom."},{"issue":"11","key":"10.1016\/j.jchromb.2017.06.029_bib0100","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/rcm.1040","article-title":"Simultaneous quantitation of enalapril and enalaprilat in human plasma by 96-well solid-phase extraction and liquid chromatography\/tandem mass spectrometry","volume":"17","author":"Lee","year":"2003","journal-title":"Rapid Commun. Mass Spectrom."},{"issue":"12","key":"10.1016\/j.jchromb.2017.06.029_bib0105","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1002\/rcm.2529","article-title":"High-throughput quantification of perindopril in human plasma by liquid chromatography\/tandem mass spectrometry: application to a bioequivalence study","volume":"20","author":"Nirogi","year":"2006","journal-title":"Rapid Commun. Mass Spectrom."},{"issue":"1","key":"10.1016\/j.jchromb.2017.06.029_bib0110","first-page":"83","article-title":"Estimation of nifedipine in human plasma by LCMS\/MS","volume":"6","author":"Reddy","year":"2013","journal-title":"Asian J. Pharm. Clin. Res."},{"issue":"5","key":"10.1016\/j.jchromb.2017.06.029_bib0115","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1134\/S1061934814050049","article-title":"A simple and rapid LC-MS\/MS method for the determination of Enalapril in human plasma for pharmacokinetic and bioequivalence studies in korean healthy volunteers under fasting conditions","volume":"69","author":"Kang","year":"2014","journal-title":"J. Anal. Chem."},{"issue":"20","key":"10.1016\/j.jchromb.2017.06.029_bib0120","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/jssc.200900287","article-title":"Rapid determination of losartan and losartan acid in human plasma by multiplexed LC-MS\/MS","volume":"32","author":"Shah","year":"2009","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.jchromb.2017.06.029_bib0125","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jpba.2016.07.049","article-title":"UHPLC-MS\/MS method with protein precipitation extraction for the simultaneous quantification of ten antihypertensive drugs in human plasma from resistant hypertensive patients","volume":"129","author":"De Nicolo","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"10008","key":"10.1016\/j.jchromb.2017.06.029_bib0130","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jchromb.2017.06.029_bib0135","series-title":"Guidance for Industry Bioanalytical Method Validation","author":"U.S. department of Health and Human Services Food and Drug Administration","year":"2001"},{"issue":"5","key":"10.1016\/j.jchromb.2017.06.029_bib0140","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3109\/03639049109051604","article-title":"Quantitation of spironolactone in the presence of canrenone using high-performance liquid-chromatography","volume":"17","author":"Pramar","year":"1991","journal-title":"Drug Dev. Ind. Pharm."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023217304981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023217304981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T20:40:42Z","timestamp":1750365642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023217304981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":28,"alternative-id":["S1570023217304981"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2017.06.029","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-throughput quantification of 8 antihypertensive drugs and active metabolites in human plasma using UPLC\u2013MS\/MS","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2017.06.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}